Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating 89Zr Panitumumab for Assessment of Indeterminate Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

NCT05747625 is registered in ClinicalTrials.gov with Eben Rosenthal as lead sponsor.

NCT NCT05747625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05747625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating 89Zr Panitumumab for Assessment of Indeterminate Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Lead sponsor
Eben Rosenthal
Phase
Phase 1
Overall status
Recruiting
Start date
May 9, 2023
Completion date
March 1, 2030
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, metastatic head and neck squamous cell carcinoma, stage iv cutaneous squamous cell carcinoma of the head and neck